Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street. Shares of BBNX remained unmoved at $15.17 apiece after the market closed today. The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million […]
Wall Street Beat
Glucotrack, Lōkahi secure financing for completed merger
Glucotrack (Nasdaq:GCTK) announced today that it secured a bridge financing to support the completion of its merger with Lōkahi Therapeutics. The bridge financing, designed to support their strategic growth objectives, allows for the completion of the combination to proceed. Glucotrack did not disclose the terms of the financing. Earlier this week, the company’s announced their […]
MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat
MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
Embecta completes Owen Mumford acquisition
Embecta (Nasdaq:EMBC) announced that it completed its previously announced acquisition of Owen Mumford Holdings Limited. Parsippany, New Jersey-based Embecta completed the deal on Friday, May 15. The former BD Diabetes business agreed to acquire Owen Mumford in March. The deal includes an upfront cash payment of approximately $133 million (£100 million). It also includes an […]
Senseonics posts mixed Q1, raises 2026 guidance amid growing Eversense 365 sales
Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
Tandem to submit tubeless pump to FDA with Street-beating Q1 on record pump shipments
Tandem Diabetes Care (Nasdaq:TNDM) today shared its plans to submit a tubeless insulin pump to the FDA. On the company’s first-quarter earnings call, President and CEO John Sheridan outlined the plans for Mobi Tubeless, the company’s existing Mobi pump that utilizes a novel infusion set option for tubeless insulin delivery. Currently, Insulet offers the leading […]
Insulet sales grow 34% in Street-beating Q1 as company ups growth guidance
Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on Wall Street. Shares of PODD ticked up 5% to $175.79 before the market opened today. However, at midday, shares were down 8.2% at $153.78 apiece, potentially in response to scrutiny over U.S. trends and new patient starts. The […]
Embecta ‘disappointed’ with Q2 results that fell below expectations, cuts 2026 guidance
Embecta (Nasdaq:EMBC) today reported second-quarter financial results that fell shy of expectations on Wall Street. The BD Diabetes spinoff attributed shortcomings to increased competitive dynamics and softness in overall market volumes in the U.S. Its international business performed in line with expectations, however. Shares of EMBC fell 43% to $5.29 apiece before the market opened […]
Senseonics amends loan facility, increases borrowing capacity to $140M
Senseonics (NYSE:SENS) announced today that it amended a loan and security agreement to increase its maximum borrowing capacity. The long-term implantable continuous glucose monitor (CGM) maker entered into the agreement with Hercules Capital. It increases its maximum borrowing capacity from $100 million to $140 million. In addition to $35 million of borrowings currently outstanding under […]
Dexcom stock dips after hours despite Q1 beats, 15% sales growth
Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months […]
